Drugmakers Expand U.S. Manufacturing as Tariff Risks Rise

Major pharmaceutical companies are committing billions of dollars to expand manufacturing and research capacity in the United States.

Reuters reported that companies are responding to tariff risk, supply-chain concerns and pressure to localize production. The investment wave could increase domestic capacity but may also reshape costs and sourcing strategies across the global drug industry.